Cytokinetics Q2 2024 GAAP EPS $(1.31) Misses $(1.02) Estimate
Portfolio Pulse from Benzinga Newsdesk
Cytokinetics (NASDAQ:CYTK) reported a Q2 2024 GAAP EPS of $(1.31), missing the analyst consensus estimate of $(1.02) by 28.43%.
August 08, 2024 | 8:42 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cytokinetics reported a Q2 2024 GAAP EPS of $(1.31), missing the analyst consensus estimate of $(1.02) by 28.43%. This significant miss is likely to negatively impact the stock price in the short term.
The significant miss on earnings per share (EPS) compared to analyst expectations is likely to result in a negative market reaction. Investors often react strongly to earnings misses, especially when the miss is as substantial as 28.43%.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100